Lexicon CEO touts ‘wonderful morning’ as diabetic pain drug clears phase 2, teeing up hopeful partnership talks

“It's a wonderful morning for Lexicon, our scientists, clinicians and the patients and principal investigators,” summed up CEO and Director Lonnel Coats, as the biotech reported results from a phase 2 trial for its diabetic neuropathy therapy.